Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 24 Week, Multicenter, Randomized, Double-Blind, Parallel Group, Phase 3 Trial With a 28 Week Long Term Safety Extension Period Evaluating the Safety and Efficacy of Dapagliflozin 10 mg in T2DM Patients Aged 10-24 Years

NCT02725593 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02725593
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02725593 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 24 Week, Multicenter, Randomized, Double-Blind, Parallel Group, Phase 3 Trial With a 28 Week Long Term Safety Extension Period Evaluating the Safety and Efficacy of Dapagliflozin 10 mg in T2DM Patients Aged 10-24 Years
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
June 22, 2016
Completion date
April 6, 2020
Enrollment
72 (actual)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes